Shukra Pharma Share Price

Shukra Pharmaceuticals Limited, together with its subsidiaries, is an Indian pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations, including tablets, capsules, and small volume parenterals. The company also provides laboratory testing services and operates through two segments: pharmaceutical and laboratory. Its product portfolio encompasses antibiotics (penicillin, cephalosporin), macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, sedatives and tranquillisers, anti-depressants, beta blockers, diuretics, analgesics, muscle relaxants, anti-tuberculosis drugs, vitamin products, anti-allergics, corticosteroids, and hyper and hypoglycemic agents. The Shukra Pharmaceuticals share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Shukra Pharmaceuticals stock price often mirrors shifts in healthcare spending, generic drug demand, and investor views on the pharmaceutical sector’s growth prospects. Factors such as the pace of new product launches, competitive intensity, raw material cost inflation, and changing regulatory frameworks influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Shukra Pharmaceuticals stock price movements.

Shukra Pharmaceuticals live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Shukra Pharmaceuticals live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Shukra Pharmaceuticals share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Shukra Pharmaceuticals Limited Company Fundamentals

a. Company Background

Shukra Pharmaceuticals Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations and laboratory testing services. It was incorporated on March 4, 1993, and is headquartered in Ahmedabad, Gujarat, India. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited effective September 22, 2016. The company has its registered office in Ahmedabad, Gujarat, and has a strong presence in the domestic and international pharmaceutical markets. Shukra Pharmaceuticals was established with the objective of manufacturing high-quality generic medicines for domestic and international markets. Over the years, the company has expanded its manufacturing capabilities with state-of-the-art facilities in Gujarat. The company has four manufacturing divisions namely tablets (general and beta lactum), capsules (general and beta lactum), liquid and small volume parental. Its manufacturing unit is located at Rakanpur in Gandhinagar, Gujarat. The company customers include leading manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, and Agenta Pharma Limited. The company has achieved WHO-GMP certification and has assisted in the development and manufacture of a wide variety of drugs and dosage forms for many prestigious pharmaceutical companies around the world. In 2013-14, the company underwent significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme.

b. Product Lines

• Tablets (general and beta lactum) and capsules (general and beta lactum)

• Liquid and small volume parenteral (injection vials and ampules)

• Antibiotics (penicillin, cephalosporin)

• Macrolides and quinolones

• Anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, and anti-anthelmintic products

• Sedative and tranquilliser, anti-depressant, anti-manic, anti-emetic, and anti-ulcer products

• Beta blockers, diuretics, analgesics, and muscle relaxants

• Anti-tuberculosis drugs and vitamin products

• Anti-allergics, corticosteroids, and hyper and hypoglycemic agents

• Laboratory testing services

• Contract manufacturing and development services

c. Company Revenue Model

• Primary revenue from the Pharmaceutical segment through sale of branded and generic formulations to domestic and international customers

• Revenue from the Laboratory segment through laboratory testing services

• Revenue from trading of pharmaceutical products

• Revenue from sale of services including processing charges and commission income

• Income from contract manufacturing and development services for other pharmaceutical companies

• Revenue from institutional sales to government healthcare programmes and hospitals

d. Geographic Presence

• Registered office located in Ahmedabad, Gujarat, India

• Strong domestic presence with manufacturing facility situated in Rakanpur, Gandhinagar, Gujarat

• International presence through exports to global markets including the Commonwealth of Independent States (CIS), Africa, and Southeast Asian countries

• Focus on expanding international footprint through strategic partnerships and regulatory approvals

• Recently received Letter of Intent from YEIDA for 10 acres of land in Medical Device Park, Greater Noida to set up a Rs 600 crore advanced manufacturing facility focused on high-end and life-saving medical technologies

• Delivery model leverages manufacturing facilities, laboratory services, and global distribution partnerships

e. Key Milestones

• 1993: Incorporated on March 4, 1993

• 2013-14: Underwent significant restructuring including amalgamation of Proper Dealcomm Private Limited through high court-approved scheme

• 2016: Name changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective September 22, 2016

• 2025: Achieved WHO-GMP certification and secured partnership with Meril Healthcare for robotic surgery projects in October 2025

• 2025: Received Letter of Intent from YEIDA for 10 acres of land in Medical Device Park, Greater Noida to set up Rs 600 crore facility

• 2026: Plans to expand into nine medical technology verticals including robotic surgery systems, diabetes monitoring devices, cardiac technologies, and imaging equipment

f. Industry Perspective: Pharmaceutical Industry in India

Shukra Pharmaceuticals operates in the global and Indian pharmaceutical industry. Globally, the pharmaceutical market continues to expand driven by ageing populations, rising chronic disease prevalence, and healthcare innovation. In India, the pharmaceutical industry is one of the largest and fastest-growing sectors. India‘s domestic pharmaceutical market is currently estimated at around $60 billion and is expected to double to about $130 billion by 2030, reflecting the sector’s scale, depth and innovation potential. The India Pharmaceutical Market size is estimated at USD 66.66 billion in 2025, and is expected to reach USD 88.86 billion by 2030, at a CAGR of 5.92% during the forecast period. According to IBEF, the Indian Pharmaceutical market stood at Rs. 4,71,295 crore (US$ 55 billion) in 2025 and is expected to grow to Rs. 10,28,280-11,13,970 crore (US$ 120-130 billion) by 2030. India‘s pharmaceutical exports crossed $30 billion in FY25, and the country stands as the third largest pharmaceutical producer by volume and 14th by value, with medicines reaching more than 200 markets. The domestic formulations market accounts for a significant portion of the total market, with generics dominating. Key growth drivers include rising healthcare expenditure, increasing penetration of health insurance, government initiatives such as the National Health Mission and Ayushman Bharat, and the production-linked incentive (PLI) scheme for pharmaceuticals. The industry faces challenges including price regulation, intense competition, raw material dependency on China, and patent expiry pressures. However, the industry outlook remains positive, supported by strong domestic demand, export growth, and the shift towards chronic therapies.

Shukra Pharmaceuticals Limited Stock Market Presence: Listings & Index Representation

Shukra Pharmaceuticals Limited is actively traded on India‘s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol SHUKRAPHAR and on the Bombay Stock Exchange (BSE) with the scrip code 524632. The ISIN number of the company’s equity shares is INE551C01044. The face value of the equity shares is ₹1 per share. Its listing on both exchanges ensures that the Shukra Pharmaceuticals share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Shukra Pharmaceuticals is included in indices such as the BSE SmallCap and Nifty Microcap 250. These index participations signal the company‘s relevance within market categories that attract both active and passive investment flows. Being represented in these indices enhances the visibility and liquidity of the Shukra Pharmaceuticals stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India‘s pharmaceutical landscape. The inclusion of Shukra Pharmaceuticals in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Shukra Pharmaceuticals Limited Stock Performance and Share Price History

The Shukra Pharmaceuticals price has displayed extraordinary volatility over the past decade, shaped by the company‘s financial performance, pharmaceutical sector cycles, and broader market trends. The Shukra Pharmaceuticals share price delivered a phenomenal return of approximately 17,600% over the past five years, surging from about ₹0.24 on March 12, 2021, to ₹41.96 on March 11, 2026. The Shukra Pharmaceuticals share price also delivered a one-year return of about 74% from March 2025 to March 2026, rising from ₹24.10 to ₹41.96. The Shukra Pharmaceuticals share price reached a 52-week high of ₹65.26 and a 52-week low of ₹11.74, indicating an extremely wide trading range and substantial price fluctuations. As of April 7, 2026, the Shukra Pharmaceuticals share price was trading at approximately ₹34.62 on the BSE, with a market capitalisation of approximately ₹1,466 crore. The Shukra Pharmaceuticals share price has shown a 3-year return of approximately 200.67% and a 5-year return of approximately 167.1%, significantly outperforming the BSE Healthcare index which delivered 23.7% and 14.0% over the same periods, respectively.

The Shukra Pharmaceuticals stock price has been particularly responsive to the company‘s strategic shift towards medical technology segments, including robotic surgery systems, imaging equipment, and cancer therapy technologies. When the company announced plans to expand into nine medical technology verticals and received a Letter of Intent for a Rs 600 crore facility in Greater Noida, the Shukra Pharmaceuticals stock price showed strong positive reactions. The Shukra Pharmaceuticals price has shown a pattern of strong positive momentum following strategic announcements and expansion plans, while periods of weak financial results have contributed to declines in the Shukra Pharmaceuticals stock price. The Shukra Pharmaceuticals share price delivered a 1-year total return of approximately 48.9% as of April 2026, outperforming the BSE Healthcare index which returned 1.3% over the same period. The Shukra Pharmaceuticals share price has shown a YTD return of approximately -46.2% as of April 2026, while the 1-month return was -22.7% and the 3-month return was -43.3%. The Shukra Pharmaceuticals share price has been influenced by corporate developments including the name change from Relish Pharmaceuticals Limited in 2016, the partnership with Meril Healthcare for robotic surgery projects, and the company‘s aggressive expansion into medical technology. The Shukra Pharmaceuticals share price has shown average weekly volatility of approximately 5-8%, which is higher than the pharmaceutical industry average. Based on data, the beta for Shukra Pharmaceuticals has been recorded at 0.44 to 1.21, indicating that the stock has exhibited varying volatility compared to the broader market. The Shukra Pharmaceuticals share price has a 10-year aggregate net profit of approximately ₹35.10 crore and a 10-year aggregate EBITDA of approximately ₹49.28 crore. The Shukra Pharmaceuticals share price has also delivered a 10-year return of 61.5% despite extreme volatility. Comprehending these patterns in the Shukra Pharmaceuticals price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Shukra Pharmaceuticals stock price movements illustrate how industry fundamentals, strategic pivots, regulatory approvals, and investor expectations converge in market pricing.

Shukra Pharmaceuticals Limited Investor Relevance and Role in Portfolio

Shukra Pharmaceuticals holds a distinctive position for portfolio investors who seek exposure to the Indian pharmaceutical sector with a focus on generic formulations and the emerging medical technology space. The company‘s diversified product portfolio across pharmaceutical formulations, laboratory testing, and expanding medical technology verticals aligns it with investment strategies that value both domestic healthcare growth and global generic demand. The Shukra Pharmaceuticals share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor healthcare spending indicators and regulatory approval metrics when evaluating allocation decisions.

Institutional stakeholders play a minimal role in Shukra Pharmaceuticals‘ ownership profile. The promoters held 50.96% of the company as of December 2025, showing a stable trend with no change from previous quarters. Mutual funds hold 0% stake in the company. Foreign Institutional Investors (FIIs) hold 0% of the company. Domestic Institutional Investors (DIIs) hold 0.11% of the company. Retail and other shareholders hold approximately 48.93% of the company. Overall institutional holding in the company stands at approximately 0.11% as of December 2025, excluding the promoter holding. The top shareholders include Anar Project Private Limited and Yogesh Biharilal Parikh. The company has no pledged promoter holdings.

Based on data, the beta for Shukra Pharmaceuticals has been recorded at 0.44 to 1.21 over different time frames, indicating varying volatility characteristics. The long-term beta shows lower volatility, while short-term beta values show higher sensitivity to market fluctuations. The Shukra Pharmaceuticals share price has shown periods of heightened responsiveness to sector-specific news, quarterly earnings releases, and regulatory announcements. The Shukra Pharmaceuticals share price reflects that the company‘s position in the pharmaceutical sector and its strategic pivot to medical technology may result in high price fluctuations. The Shukra Pharmaceuticals stock price is thus viewed as a high-risk, high-reward opportunity within a portfolio context with extreme volatility characteristics.

Shukra Pharmaceuticals Limited Sectoral Relevance and Peer Positioning

The sector relevance of Shukra Pharmaceuticals is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified generic drug manufacturers. As part of this industry, the company‘s strategic positioning connects pharmaceutical formulations, laboratory testing, and medical technology verticals that serve multiple healthcare segments. Competitors in adjacent segments include companies such as Sun Pharmaceutical Industries Limited, Divi‘s Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Dr. Reddy‘s Laboratories Limited, Lupin Limited, Aurobindo Pharma Limited, Mankind Pharma Limited, and Zydus Life Sciences Limited. Larger players such as Sun Pharma and Divi’s Labs have larger scale and diversified portfolios, though Shukra Pharmaceuticals competes in the small-cap generic formulation segment. Firms with parallels in either manufacturing scale or therapeutic focus are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Shukra Pharmaceuticals P/E ratio tend to reflect narrative shifts in earnings expectations and investor confidence relative to these peers. The Shukra Pharmaceuticals P/E ratio stood at approximately 47.9-59.0 as of April 2026, compared to the industry P/E of 44.74, indicating that the stock is trading at a premium to the industry average. The Shukra Pharmaceuticals earnings history over the past five years has shown a pattern of extreme volatility. Revenue increased from ₹11.20 crore in FY2021 to ₹20.49 crore in FY2022, to ₹58.83 crore in FY2023, to ₹74.57 crore in FY2024, before declining to ₹32.59 crore in FY2025, representing a 5-year growth that has been inconsistent. Net profit increased from ₹0.19 crore in FY2021 to ₹0.75 crore in FY2022, to ₹4.41 crore in FY2023, to ₹18.54 crore in FY2024, before easing to ₹9.58 crore in FY2025. For the December 2025 quarter (Q3 FY26), revenue stood at ₹39.13 crore and net profit at ₹20.36 crore, reflecting strong year-on-year growth. The 10-year aggregate net profit of the company stands at approximately ₹35.10 crore. The Shukra Pharmaceuticals EPS narrative has followed a similar pattern of volatility. EPS (TTM) has been recorded at approximately ₹0.70-₹0.80 over different periods, with a current TTM EPS of approximately ₹0.67. Basic EPS increased from ₹0.01 in FY2021 to ₹0.17 in FY2022, to ₹1.01 in FY2023, to ₹4.23 in FY2024, before declining to ₹2.19 in FY2025. The Shukra Pharmaceuticals market cap has shown a pattern of explosive growth over the past decade. Shukra Pharmaceuticals market cap increased from approximately ₹7 crore in 2021 to approximately ₹1,837 crore at its peak, before declining to approximately ₹1,396-₹1,466 crore as of April 2026. This directional behaviour in valuation multiples demonstrates how market expectations around growth prospects and earnings durability influence broader assessment of the Shukra Pharmaceuticals share price within its industry context. The Shukra Pharmaceuticals stock price remains a high-volatility instrument in the pharmaceutical segment.

Over the last ten years, Shukra Pharmaceuticals market cap has shown a pattern of explosive growth. The company‘s market cap increased from approximately ₹7 crore in 2021 to approximately ₹1,837 crore at its peak, before declining to approximately ₹1,466 crore as of April 2026. The market cap has shown a 10-year aggregate net profit of approximately ₹35.10 crore, a 10-year aggregate EBITDA of approximately ₹49.28 crore, and a 10-year aggregate CFO of approximately ₹19.18 crore. The current market cap stands at approximately ₹1,466 crore, having ranged between lower levels and its current value over the past decade.

Shukra Pharmaceuticals earnings, in terms of net profit, have exhibited a pattern of extreme volatility over the past decade. Net profit increased from ₹0.19 crore in FY2021 to ₹0.75 crore in FY2022, to ₹4.41 crore in FY2023, to ₹18.54 crore in FY2024, before easing to ₹9.58 crore in FY2025. The 10-year aggregate net profit of the company stands at approximately ₹35.10 crore. Quarterly net profit for the December 2025 quarter rose strongly to ₹20.36 crore. Revenue increased from ₹11.20 crore in FY2021 to ₹20.49 crore in FY2022, to ₹58.83 crore in FY2023, to ₹74.57 crore in FY2024, before declining to ₹32.59 crore in FY2025. For Q3 FY26, revenue stood at ₹39.13 crore, reflecting strong recovery.

Shukra Pharmaceuticals EPS history over the past decade has shown a pattern of extreme volatility. EPS (TTM) has been recorded at approximately ₹0.70-₹0.80 over different periods, with a current TTM EPS of approximately ₹0.67. Basic EPS increased from ₹0.01 in FY2021 to ₹0.17 in FY2022, to ₹1.01 in FY2023, to ₹4.23 in FY2024, before declining to ₹2.19 in FY2025. The 10-year EPS growth rate has been approximately 62.81%, reflecting the company‘s enhanced profitability on a per-share basis from very low bases, though with significant volatility.

Shukra Pharmaceuticals P/E ratio history has shown a pattern of extreme variation, fluctuating between moderate and extremely elevated levels over the past decade. The P/E ratio stood at approximately 47.9-59.0 as of April 2026, compared to the industry P/E of 44.74. The P/E ratio has ranged from approximately 15.1x to 184.8x over different periods. This valuation premium reflects that investor expectations remain anchored to the company‘s earnings growth trajectory and strategic pivot into medical technology, despite significant earnings volatility.

Summary

Shukra Pharmaceuticals is a small-cap Indian pharmaceutical company listed on both the NSE and BSE, where the Shukra Pharmaceuticals share price reflects healthcare demand cycles, regulatory approvals, and the company‘s strategic pivot into medical technology. Its representation in stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical consumption patterns. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the Indian generic drug market.